Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Apr 24, 2025; 16(4): 102735
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.102735
Pretreatment radiomic imaging features combined with immunological indicators to predict targeted combination immunotherapy response in advanced hepatocellular carcinoma
Xu Zhang, Xu Zhang, Qian-Kun Luo, Qiang Fu, Pan Liu, Chang-Jie Pan, Chuan-Jiang Liu, Hong-Wei Zhang, Tao Qin
Xu Zhang, Xu Zhang, Qian-Kun Luo, Qiang Fu, Pan Liu, Chang-Jie Pan, Chuan-Jiang Liu, Hong-Wei Zhang, Tao Qin, Department of Hepato-Biliary-Pancreatic Surgery, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital, Zhengzhou 450003, Henan Province, China
Co-first authors: Xu Zhang and Xu Zhang.
Co-corresponding authors: Hong-Wei Zhang and Tao Qin.
Author contributions: Zhang X (first) performed the majority of the experiments, and Zhang X (second) was responsible for article correction, they contributed equally as co-first authors; Luo QK conducted the experimental analysis; Fu Q provided vital reagents; Liu P and Pan CJ analyzed the data and developed the analysis tools; Liu CJ analyzed the clinical data; Zhang HW and Qin T supervised the research, they contributed equally as co-corresponding authors; and all authors have read and approved the final manuscript.
Supported by Natural Science Foundation of Henan Province, No. 242300421286; the research and practice project of higher education reform in Henan Province, No. 2023SJGLX124Y; and the research and practice project of higher education reform of Zhengzhou University, No. 2023ZZUJGXM114.
Institutional review board statement: This study was approved by the Ethics Committee of Zhengzhou University People’s Hospital (2022, Ethics No. 33).
Informed consent statement: This study is a retrospective study and meets the criteria for exemption from signing Informed Consent Form(s).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data that support the findings of this study are available on request from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao Qin, PhD, Professor, Department of Hepato-Biliary-Pancreatic Surgery, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450003, Henan Province, China. goodfreecn@163.com
Received: October 28, 2024
Revised: December 16, 2024
Accepted: January 23, 2025
Published online: April 24, 2025
Processing time: 150 Days and 2.4 Hours
Core Tip

Core Tip: In recent years, molecular-targeted drugs combined with immunotherapy and other therapeutic methods have provided new treatment options for mid-to-advanced hepatocellular carcinoma, and predicting the effect of targeted combined immunotherapy has become a hot topic in current research. The degree of enhancement of advanced hepatocellular carcinoma nodules in the hepatobiliary stage on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging was significantly correlated with progression-free survival. The imaging information of nodules in the hepatobiliary stage and clinical immunological indicators have high predictive efficacy for targeted combined immunotherapy and are associated with progression-free survival in patients.